FUNI.US Hypha Labs, Inc.
- Market cap
- USD 475K
- P/E
- -
- P/B
- 11.43x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is FUNI.US undervalued?
Graham numberThe Graham number of Hypha Labs, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hypha Labs, Inc. fundamental analysis
No fundamental analysis for Hypha Labs, Inc. yet.
Hypha Labs, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hypha Labs, Inc.
Hypha Labs, Inc., engages in the research, development, and commercialization of a bioreactor in the United States. It offers Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human consumption. Hypha Labs, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.
Full company profileHypha Labs, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hypha Labs, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 819K | 1.90M | 2.84M | 2.55M | 2.57M | 2.50M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 439K | 994K | 770K | 840K | 796K | 715K | 1.07M | 0.00 | 0.00 | 0.00 | -32.0K |
| Operating Income | -2.88M | -1.30M | -1.76M | -1.84M | -1.56M | -772K | -1.93M | -262K | -1.37M | -3.00M | -1.32M |
| EBITDA | -2.64M | -1.01M | -1.38M | -1.48M | -1.84M | -249K | -1.73M | -58.2K | -1.37M | -2.95M | -1.27M |
| Net Income | -3.70M | -1.07M | -1.65M | -1.81M | -2.31M | -687K | -2.06M | 247K | -785K | -3.10M | -1.80M |
| EPS | -0.20 | -0.04 | -0.04 | -0.04 | -0.04 | -0.01 | -0.03 | 0.00 | -0.01 | -0.02 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 1.45M | 1.57M | 1.40M | 1.36M | 1.79M | 1.89M | 1.34M | 1.41M | 494K | 409K | 68.3K |
| Total Liabilities | 212K | 164K | 385K | 930K | 2.88M | 2.94M | 4.08M | 3.28M | 1.42M | 2.51M | 3.16M |
| Shareholders' Equity | 1.23M | 1.41M | 1.01M | 426K | -1.09M | -1.05M | -2.41M | -1.87M | -927K | -2.10M | -3.09M |
| Cash & Short-term Investments | 135K | 178K | 176K | 324K | 82.7K | 296K | 56.2K | 271K | 91.2K | 38.1K | 5.11K |
| Total Debt | - | - | - | 659K | 2.77M | 2.79M | 2.35M | 2.29M | 1.14M | 1.65M | 1.79M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -734K | -377K | -163K | -1.04M | -672K | -136K | -185K | 113K | -1.39M | -380K | -337K |
| Capital Expenditure | 13.8K | 141K | 207K | 45.1K | 141K | 56.2K | 17.7K | 5.00 | 27.7K | 33.0K | 8.00 |
| Free Cash Flow | -748K | -518K | -371K | -1.09M | -813K | -192K | -203K | 113K | -1.42M | -413K | -337K |
| Ratios | |||||||||||
| ROE | -299.5% | -75.7% | -163.0% | -423.8% | - | - | - | - | - | - | - |
| ROA | -255.7% | -67.8% | -118.2% | -133.1% | -129.1% | -36.4% | -153.5% | 17.5% | -159.0% | -758.0% | -2,629.5% |
| Net Profit Margin | -451.9% | -56.1% | -58.2% | -70.7% | -89.7% | -27.4% | -76.2% | - | - | - | - |
| Debt to Equity | - | - | - | 1.55x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hypha Labs, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 192K | 0.00 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on May 27, 2015.
Who owns Hypha Labs, Inc.
- Insiders 20.33%
- Institutions 0.00%
- Public & others 79.67%
- Shares outstanding 164M
- Free float 131M
Hypha Labs, Inc. company profile
- Company name
- Hypha Labs, Inc.
- Ticker
- FUNI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 5
- Fiscal year end
- September
- Address
- 5940 S. Rainbow Boulevard, Las Vegas, NV, United States, 89118
- Phone
- 702 744 0640
- Website
- hyphalabs.com
About Hypha Labs, Inc.
Hypha Labs, Inc., engages in the research, development, and commercialization of a bioreactor in the United States. It offers Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human consumption. Hypha Labs, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.
Hypha Labs, Inc. management
3- Mr. A. Stone DouglassChairman, President, CEO, CFO & Secretary · born 1948
- Mr. John FraileyChief Technical Director
- Mr. Craig M. EllinsChief Science Officer · born 1952